Quotient Clinical

From Some Degree of transparency
Jump to: navigation, search
Quotient Clinical, Ltd.
Private
Industry Pharmaceutical/medical devices
Founded 1990; 27 years ago (1990)
Headquarters Nottingham, United Kingdom
Key people
Mark Egerton (CEO)[1]
Number of employees
600
Website Official website

Quotient Clinical is an early phase drug development services provider founded in 1990 and headquartered in Nottingham. Quotient’s flagship "Translational Pharmaceutics" platform integrates clinical testing with formulation development and real-time GMP manufacturing.

As part of a global expansion strategy, Quotient has acquired three businesses with complementary service portfolios. QS Pharma, SeaView Research[2] and Co-Formulate[3] all reside within the Quotient group, increasing the scale of the Quotient business to approximately 600 employees across 5 sites and with more than 150 clients.

Translational Pharmaceutics[edit]

Translational Pharmaceutics is an novel approach to drug product development and manufacture, established in 2008.[4] It horizontally integrates across the conventional CRO and CDMO outsourcing industries, which have traditionally seen separate activities performed by different organisations.[5] It is designed to simplify the outsourcing of clinical phase development. This approach integrates formulation development, GMP manufacturing and clinical testing within a single organisation. It enables a more rapid transfer of drug products from the GMP manufacturing suite into the clinical pharmacology unit creating the capability to modify dose and formulation compositions in response to clinical data (safety, pharmacokinetic or pharmacodynamic).

The approach can be applied to a wide range of drug products, including oral, inhaled, dermal and IV, and encompasses simple and complex formulation types.

References[edit]

Cite error: Invalid <references> tag; parameter "group" is allowed only. Use <references />, or <references group="..." />

External links[edit]

  • ^ http://www.bloomberg.com/research/stocks/private/person.asp?personId=2746286&privcapId=47519532
  • ^ http://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=47519532
  • ^ https://www.cambridgenetwork.co.uk/news/quotient-clinical-expands-its-formulation-development-servic7794/
  • ^ Scholes P.D, Stevens L.A, Paterson M, Egerton M; 2009. "Translational Pharmaceutics - interactive Drug Development to enable rapid optimisation of drug products in early development"
  • ^ Sweet S, Collier J, Connor A, Paterson M, Collis P, Sheridan W, El-Kattan Y. 2014. “A First-in-Human (FIH) Study of BCX4161, an Oral Kallikrein Inhibitor, using a Translational Pharmaceutics Platform”